- Home
- ALZN vs RDHL Comparison
ALZN vs RDHL Comparison
Compare ALZN & RDHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ALZN
- RDHL
- Stock Information
- Founded
- ALZN 2016
- RDHL 2009
- Country
- ALZN United States
- RDHL Israel
- Employees
- ALZN N/A
- RDHL N/A
- Industry
- ALZN Medicinal Chemicals and Botanical Products
- RDHL Biotechnology: Pharmaceutical Preparations
- Sector
- ALZN Health Care
- RDHL Health Care
- Exchange
- ALZN Nasdaq
- RDHL Nasdaq
- Market Cap
- ALZN 6.1M
- RDHL 6.8M
- IPO Year
- ALZN 2021
- RDHL N/A
- Fundamental
- Price
- ALZN $1.00
- RDHL $2.57
- Analyst Decision
- ALZN Strong Buy
- RDHL
- Analyst Count
- ALZN 1
- RDHL 0
- Target Price
- ALZN $20.00
- RDHL N/A
- AVG Volume (30 Days)
- ALZN 210.7K
- RDHL 120.6K
- Earning Date
- ALZN 03-10-2025
- RDHL 04-11-2025
- Dividend Yield
- ALZN N/A
- RDHL N/A
- EPS Growth
- ALZN N/A
- RDHL N/A
- EPS
- ALZN N/A
- RDHL N/A
- Revenue
- ALZN N/A
- RDHL $3,707,000.00
- Revenue This Year
- ALZN $322.64
- RDHL $224.90
- Revenue Next Year
- ALZN N/A
- RDHL $82.69
- P/E Ratio
- ALZN N/A
- RDHL N/A
- Revenue Growth
- ALZN N/A
- RDHL N/A
- 52 Week Low
- ALZN $0.64
- RDHL $2.47
- 52 Week High
- ALZN $15.06
- RDHL $20.28
- Technical
- Relative Strength Index (RSI)
- ALZN 51.86
- RDHL 30.12
- Support Level
- ALZN $0.95
- RDHL $2.62
- Resistance Level
- ALZN $1.13
- RDHL $2.90
- Average True Range (ATR)
- ALZN 0.09
- RDHL 0.22
- MACD
- ALZN 0.02
- RDHL 0.09
- Stochastic Oscillator
- ALZN 65.13
- RDHL 28.36
About ALZN Alzamend Neuro Inc.
Alzamend Neuro Inc is an early clinical-stage biopharmaceutical company. It is focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders, including Alzheimer's. Its mission is to develop and market safe and effective treatments. The company's pipeline consists of two novel therapeutic drug candidates, AL001 - a patented ionic cocrystal technology delivering lithium via a therapeutic combination of lithium, proline and salicylate, and AL002 - a patented method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine that seeks to restore the ability of a patient's immunological system to combat Alzheimer's.
About RDHL Redhill Biopharma Ltd.
Redhill Biopharma Ltd is a specialty biopharmaceutical company focused on gastrointestinal diseases. The company is focused primarily on the advancement of its development pipeline of clinical-stage therapeutic candidates. The company also commercializes in the U.S. GI-related products, Talicia (omeprazole, amoxicillin, and rifabutin) and Aemcolo (rifamycin). The company's current pipeline consists of five therapeutic candidates, which are Opaganib, RHB-107, RHB-102, RHB-204, and RHB-104, most of which are in clinical development.